ST. GEORGE — MyID LLC, an electronic medical records company engaged in the development and commercialization of app-based health management platforms, today announced that it has launched its partnership with Merck & Co. Inc., Kenilworth, N.J., USA to provide the MyID mobile app and wristband to patients in the United States, including St. George, who are being treated with their number one selling drug, KEYTRUDA. KEYTRUDA (Pembrolizumab) is a humanized antibody used in cancer immunotherapy that includes treatment for melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
Brian Norton, MyID Board Chairman, commented, “We are excited to be partnering with Merck & Co. Inc., to help provide important medical information about the appropriate clinical treatment for patients who have been prescribed KEYTRUDA® in the U.S. This partnership is aligned with our corporate strategy to help patients effectively manage chronic disease states. Cancer immunotherapy drug treatment is an excellent fit in our portfolio, with a clearly defined customer base, that will create synergies and scale with our commercial team.”
“Our new partnership with Merck provides us the opportunity to build a flexible and scalable commercial infrastructure that enables us to demonstrate the benefits of the MyID platform.” Stated Eric K. Olson, Chief Executive Officer. The KEYTRUDA and MyID product combo will allow clinicians and first responders to effectively treat patients with the appropriate use of this cancer immunotherapy drug. We look forward to educating clinicians about the differentiating attributes of both products and bringing these important treatment options to patients.”
For more than 7 years, MyID has allowed patients to control their medical records and to securely share this information with clinicians. The agreement with Merck allows the company to continue that commitment by driving innovation in the pharmaceutical marketplace.
Under the terms of the agreement, Merck will procure product directly from MyID, LLC, and will be responsible for providing it to their KEYTRUDA patients in the U.S. through Dec. 31, 2023.